← Back to Clinical Trials
Recruiting NCT06575322

NCT06575322 Effects of Neoadjuvant Therapy With Carboplatin, Paclitaxel Combined With Anti-PD-1 Drugs on Pain, Anxiety and Depression in Patients With Resectable Head and Neck Squamous Cell Carcinoma

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06575322
Status Recruiting
Phase
Sponsor Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Condition Head and Neck Squamous Cell Carcinoma
Study Type OBSERVATIONAL
Enrollment 302 participants
Start Date 2024-09-01
Primary Completion 2026-09-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 80 Years
Study Type OBSERVATIONAL
Interventions
Carboplatin( neoadjuvant)Paclitaxel (neoadjuvant)Anti-PD-1 Drugs

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 302 participants in total. It began in 2024-09-01 with a primary completion date of 2026-09-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this observational study is to learn about the Effects of neoadjuvant therapy with carboplatin, paclitaxel combined with anti-PD-1 drugs on pain, anxiety and depression in patients with operable head and neck squamous cell carcinoma: a prospective cohort study

Eligibility Criteria

Inclusion Criteria: \- 1: Clinical diagnosis of head and neck squamous cell carcinoma (stage I-IVA), without prior treatment, and planning to undergo either surgical treatment alone or surgical treatment combined with chemotherapy and immunotherapy. 2: Ability to speak Chinese and possess basic reading and writing skills. Exclusion Criteria: * 1: Presence of mental illnesses such as dementia or delirium. 2: Active use of narcotic drugs, including consuming alcohol more than 4 times per day or more than 4 times per week. 3: Patients who alter their treatment plan during the course of treatment. 4: Current or prior use of antidepressants.

Contact & Investigator

Central Contact

Song Fan, Doctor

✉ fansong2@mail.sysu.edu.cn

📞 13570536658

Principal Investigator

Song Fan, Doctor

STUDY CHAIR

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Frequently Asked Questions

Who can join the NCT06575322 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Head and Neck Squamous Cell Carcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06575322 currently recruiting?

Yes, NCT06575322 is actively recruiting participants. Contact the research team at fansong2@mail.sysu.edu.cn for enrollment information.

Where is the NCT06575322 trial being conducted?

This trial is being conducted at Guanzhou, China.

Who is sponsoring the NCT06575322 clinical trial?

NCT06575322 is sponsored by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University. The principal investigator is Song Fan, Doctor at Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University. The trial plans to enroll 302 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology